Skip to main content
Contact Us

Author Archives: XDS

Newer posts

SoundBite Medical Solutions is the recipient of the 2020 “National Award for an Engineering Project or Achievement” by Engineers Canada

Posted on by
artery

MONTREAL, June 17, 2020 – SoundBite Medical Solutions Inc. (SBMS) today announced that it was granted by Engineers Canada, the national organization of the 12 provincial and territorial associations that regulate the practice of engineering in Canada, the 2020 “National Award for an Engineering Project or Achievement”. The awards acknowledge exemplary community and professional involvement, contributions to engineering education, support for women in engineering, contributions by engineers and engineering students to Canadian society, and remarkable engineering projects or achievements.

“The innovative SoundBite technology directly addresses the medical problem of chronic total occlusions by treating patients, who were incurable until now, with a low-cost technology that requires only a short hospital stay. The SoundBite technology will have a wide-reaching impact, including helping address the critical medical problem of total chronic occlusions, and fostering a new wave of medical device entrepreneurs in Canada” wrote Engineers Canada in its announcement.

“This award is the direct product of the sustained efforts of our team of dedicated employees, and we are honored to contribute to the visibility of Québec’s engineering expertise at home and abroad” said Martin Brouillette, Founder and SoundBite’s Chief Technology Officer.

“It is a great honor to be recognized by its peers at the national level. This award validates the potential offered by SoundBite’s technology to become a game changer in the treatment of CTOs” said Francis Bellido, SoundBite’s CEO.

About SoundBite Medical Solutions
SoundBite is a privately held medical device company developing products in the field of vessel preparation for the management and treatment of calcified and occlusive lesions in coronary and peripheral arterial diseases. SoundBite will leverage its shockwave technology platform to clinically and commercially validate its calcium management medical devices with active wires and microcatheters. Peripheral artery disease (PAD) and coronary artery disease (CAD) affect more than 12 million & 16 million people in the US, respectively.
For additional information visit www.soundbitemedical.com or communicate with Francis Bellido, CEO ([email protected]), SoundBite Medical Solutions, 2300 Alfred Nobel, Technoparc St-Laurent, Montreal Québec H4S 2A4

Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances

SoundBite Receives FDA IDE Approval for the ACTIVE Clinical Study with the SoundBite™ Crossing System – Coronary

Posted on by
artery

MONTREAL – February 3, 2020 – SoundBite Medical Solutions Inc. (SBMS) announced today that it has received FDA IDE (Investigational Device Exemption) approval to start the ACTIVE Clinical Study with the SoundBite™ Crossing System – Coronary in the USA, a unique and novel active guidewire technology for use in the treatment of coronary chronic total occlusions (CTOs).

“After the recent 510(k) clearance for our SoundBite™ Crossing System – Peripheral, we are very pleased with this FDA approval which allows us to accelerate the development of the coronary application for our active wire technology in the USA, and to bring patients and physicians an innovative new tool to address calcific difficult-to-treat CTOs,” said Francis Bellido, CEO of SoundBite Medical.

FDA IDE Approval indicates that SBMS has provided sufficient data to support initiating an IDE to evaluate the safety and effectiveness of the SoundBite™ Crossing System – Coronary through a multi-center study in the US as well as Canada, where the study has already started.

About SoundBite Medical Solutions Inc.

SoundBite Medical Solutions Inc. is developing proprietary shock wave technology to address significant unmet clinical needs in interventional vascular treatment. Through an elegant combination of hardware and software, it can, in a very controllable manner, deliver high amplitude shock wave pulses through guidewires and other interventional tools, to specifically attack highly calcified and fibrotic tissue in the vascular system, while leaving healthy, elastic arterial walls unharmed.

For information on SoundBite Medical Solutions, please contact Mandy Di Lazzaro, Director, Human Resources & Communications ([email protected]) or Francis Bellido, CEO ([email protected]), SoundBite Medical Solutions, 2300 Alfred Nobel, Technoparc St-Laurent, Montreal Québec H4S 2A4
For additional information visit www.soundbitemedical.com

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.

SoundBite Receives FDA 510(k) Clearance of the SoundBite™ Crossing System – Peripheral

Posted on by
artery

MONTREAL January 21, 2020 – SoundBite Medical Solutions Inc. (SBMS) today announces it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SoundBite™ Crossing System, a unique active wire technology for use in the treatment of peripheral chronic total occlusions (CTOs).

“Through our collaborative approach with the FDA, we met the regulatory requirements and transformed a novel technology into a commercial product,” said Marc-André Côté, Director, Regulatory Affairs of SoundBite.

FDA 510(k) clearance indicates that the product complies with the requirements of 21 CFR 807 Subpart E and is authorized to be distributed and commercialized in the USA market.

“This significant milestone is very gratifying for all SoundBite employees who deployed an incredible amount of dedication and effort to make it happen. This also allows us to bring this innovative treatment solution to clinicians and their patients suffering from difficult-to-treat calcific PAD (Peripheral Artery Disease) in the US,” said Francis Bellido, CEO of SoundBite.

About SoundBite Medical Solutions Inc.

SoundBite Medical Solutions Inc. is developing proprietary shock wave technology to address significant unmet clinical needs in interventional vascular treatment. Through an elegant combination of hardware and software, it can, in a very controllable manner, deliver high amplitude shock wave pulses through guidewires and other interventional tools, to specifically attack highly calcified and fibrotic tissue in the vascular system, while leaving healthy, elastic arterial walls unharmed.

For information on SoundBite Medical Solutions, please contact Mandy Di Lazzaro, Director, Human Resources & Communications ([email protected]) or Francis Bellido, CEO ([email protected]), SoundBite Medical Solutions, 2300 Alfred Nobel, Technoparc St-Laurent, Montreal Québec H4S 2A4
For additional information visit www.soundbitemedical.com

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.

SoundBite Announces Health Canada Approval of the SoundBite™ Crossing System – Peripheral

Posted on by
artery

MONTREAL December 4, 2019 – SoundBite Medical Solutions Inc. (SBMS) is pleased to announce that it has received a Health Canada Medical Device License for the SoundBite™ Crossing System – Peripheral.

“We are pleased to have obtained our first approval in North America for the clinical use of the SoundBite™ Crossing System – Peripheral and thank the employees, clinicians, patients and other stakeholders that made this possible,” said Francis Bellido, CEO of SoundBite. “This approval allows us to commercialize this innovative technology in its country of origin, Canada, which will also facilitate our ability to pursue approval in other countries.”

About SoundBite Medical Solutions Inc.

SoundBite Medical Solutions Inc. is developing proprietary shock wave technology to address significant unmet clinical needs in interventional vascular treatment. Through an elegant combination of hardware and software, it can, in a very controllable manner, deliver high amplitude shock wave pulses through guidewires and other interventional tools, to specifically attack highly calcified and fibrotic tissue in the vascular system, while leaving healthy, elastic arterial walls unharmed.

For information on SoundBite Medical Solutions, please contact Mandy Di Lazzaro, Director, Human Resources & Communications ([email protected]) or Francis Bellido, CEO ([email protected]), SoundBite Medical Solutions, 2300 Alfred Nobel, Technoparc St-Laurent, Montreal Québec H4S 2A4
For additional information visit www.soundbitemedical.com

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.

SoundBite Medical Solutions Inc. and Asahi Intecc Sign Distribution Agreement for Japan

Posted on by
artery

Asahi Intecc will be Exclusive Japanese Provider of the SoundBite™ Crossing System – Peripheral

MONTREAL – December 3, 2019 – SoundBite Medical Solutions Inc. (SBMS) has signed an exclusive distribution agreement with Asahi Intecc Co., Ltd. (“Asahi Intecc”) to sell its SoundBite™ Crossing System in Japan.

Asahi Intecc is recognized globally as a leading manufacturer and provider of guidewires and catheters among other medical devices used by hospitals for cardiovascular interventions in over 108 countries and regions across the globe.

“We are excited to build on our strategic partnership with Asahi Intecc and to bring the SoundBite system to patients suffering from peripheral vascular disease in Japan. We look forward to this collaboration and to leveraging Asahi Intecc’s market leadership and experience to expand our reach and establish our innovative technology in this important market,” said Ashkan Haghighat, Vice-President, Business and Corporate Development at SBMS.

“This important distribution agreement with one of the most respected manufacturers of guidewires is further evidence of the enthusiasm SoundBite’s technology is creating in the vascular cardiology industry,” said Francis Bellido, CEO of SBMS. “Under Asahi Intecc’s guidance and strong local presence, we believe to now have all the resources necessary to create a great success story in Japan.”

“We are very pleased to bring the innovative device developed by SoundBite to the Japanese peripheral vascular market. We believe that a strong synergy effect will be generated between Asahi Intecc brand’s long-standing reputation for high quality and high performance in the Japanese market and SoundBite’s innovative product and technology. The SoundBite system is very effective for calcified lesions that continue to pose a major treatment challenge, often due to conventional guidewires failing to cross the lesion. We anticipate that the system will contribute to saving many patients that otherwise would not have been treatable.” said Masahiko Miyata, President and CEO, Asahi Intecc Co., Ltd.

The SoundBite™ Crossing System – Peripheral is used to facilitate the intra-luminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions. The SoundBite™ Crossing System – Peripheral consists of a re-usable console, the SoundBite™ Console, and a disposable wire, the SoundBite™ Active Wire.

About SoundBite Medical Solutions Inc.

SoundBite Medical Solutions Inc. is developing proprietary shock wave technology to address significant unmet clinical needs in interventional vascular treatment. Through an elegant combination of hardware and software, it can, in a very controllable manner, deliver high amplitude shock wave pulses through guidewires and other interventional tools, to specifically attack highly calcified and fibrotic tissue in the vascular system, while leaving healthy, elastic arterial walls unharmed.

For information on SoundBite Medical Solutions, please contact Mandy Di Lazzaro, Director, Human Resources & Communications ([email protected]) or Francis Bellido, CEO ([email protected]), SoundBite Medical Solutions, 2300 Alfred Nobel, Technoparc St-Laurent, Montreal Québec H4S 2A4
For additional information visit www.soundbitemedical.com

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.

SoundBite Medical Solutions Announces $8M Loan Agreement with Investissement Québec

Posted on by
artery

MONTREAL – September 24, 2019 – SoundBite Medical Solutions Inc. (SBMS) today announced that it has entered into an $8 million loan agreement (the “Agreement”) with Investissement Québec (IQ) as part of the Biomed Propulsion Program. The terms of the Agreement were not disclosed.

SoundBite intends to use the proceeds to support the development and early market introduction of its SoundBite™ Crossing System (SCS). The first application, the SCS-Peripheral has received CE Mark, and SoundBite has filed for market authorization in Canada and the US.

The Biomed Propulsion Program, which is under the responsibility of the “Ministère de l’Economie et de l’innovation du Québec” is administered by IQ.

“We are excited to have the support of Investissement Québec, a high-profile Canadian investment institution, as we execute on our strategic plan and continue to grow and prepare for early market introduction of our first approved product,” said Francis Bellido, SBMS President and CEO.

“This financing option provides a flexible and cost-effective way to fund programs and deliver tangible value while avoiding dilution for our investors at this juncture of our growth trajectory,” said Ashkan Haghighat, VP Business and Corporate Development at SBMS.

About SoundBite Medical Solutions Inc.

SoundBite Medical Solutions Inc. is developing proprietary shock wave technology to address significant unmet clinical needs in interventional vascular treatment. Through an elegant combination of hardware and software, it can, in a very controllable manner, deliver high amplitude shock wave pulses through guidewires and other interventional tools, to specifically attack highly calcified and fibrotic tissue in the vascular system, while leaving healthy, elastic arterial walls unharmed.

For information on SoundBite Medical Solutions, please contact Mandy Di Lazzaro, Director, Human Resources & Communications ([email protected]) or Francis Bellido, CEO ([email protected]), SoundBite Medical Solutions, 2300 Alfred Nobel, Technoparc St-Laurent, Montreal Québec H4S 2A4

For additional information visit www.soundbitemedical.com

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.

SoundBite Medical Solutions Announces New Appointments to its Board of Directors

Posted on by
artery

MONTREAL – September 23, 2019 – SoundBite Medical Solutions Inc. (SBMS) today announced the appointments of William L Hunter, MD, Azin Parhizgar, PhD and Rick Geoffrion to the Board of Directors.
“We are extremely excited and pleased to welcome these three medical device industry veterans. Their deep business expertise in Interventional Cardiology will be invaluable to SoundBite and we are confident that their broad experiences with both emerging and multinational healthcare companies will significantly strengthen and extend the reach of our Board,” said Dr. Francis Bellido, President and Chief Executive Officer of SoundBite Medical. “We are also very pleased that Dr. Hunter has accepted to act as Chairman of the Board,” added Dr. Bellido.

Bill Hunter, MD is Founder, President & Chief Executive Officer of Canary Medical. Dr. Hunter is a senior healthcare leader with over 20 years’ experience as a public company CEO in both medical device and specialty pharmaceutical companies. He has spent his career examining ways to make medical devices “smarter” and more effective through the use of technologies borrowed from outside the industry such as pharmaceutical coatings, surface modification and sensor technologies. As an inventor with over 200 patents and patent applications to his name, he has been involved in the discovery and development of the TAXUS® Drug-Eluting Coronary Stent, the Zilver PTX Peripheral Drug-Eluting Stent, and the Quill barbed wound closure device; combined these products have been used in over 40 million patients and recorded revenues of over $25 billion. Dr. Hunter was Co-Founder of Angiotech Pharmaceuticals and served as its President and Chief Executive Officer from 1997-2011. He was also President & Chief Executive Officer of Correvio (formerly Cardiome).

Azin Parhizgar, PhD is an experienced and highly successful medical device industry Executive and serial entrepreneur currently serving on a number of industry and academic board positions. Most recently she served as President and Chief Executive Officer of Claret Medical, Inc., an embolic protection company, transforming the company from an early stage venture-backed company to a successful revenue-stage company, and leading to the company’s sale to Boston Scientific Corporation. Her previous experiences include serving as Chief Operating Officer of Conor Medsystems Inc., Executive Vice President of Clinical, Regulatory, and Quality Engineering at Arterial Vascular Engineering (AVE), and management positions at J&J, CR Bard, and Summit technologies. Dr. Parhizgar has served as an advisor to emerging medical device technology companies including several Board of Directors and Scientific Advisory Board positions throughout her career.

Rick Geoffrion currently serves as the President and Chief Executive Officer of Cyrano Therapeutics, a venture-backed private company that has developed a treatment to restore function in patients experiencing a chronic loss of smell and flavor. He is a member of the Executive Committee and the Board of the Medical Device Innovation Consortium (MDIC). Rick has more than 35 years of management experience in the medical device industry with over 30 years focus in the cardiovascular device space. Prior to Cyrano, he was the President and CEO of Mitralign, which sold to Edwards Lifesciences in March of 2019. Prior to Mitralign, Mr. Geoffrion served as the President and CEO of Accelerated Technologies, a medical device incubator. In this role he co-founded and led the recapitalization and redirection of six cardiovascular medical device companies (Impella which was acquired by Abiomed, Pathway Medical which was acquired by Bayer, CircuLite which was acquired by Heartware, FlowMedica which was acquired by Angiodynamics, Mitralign and X-Cell). Mr. Geoffrion served on the Accel Board of Directors at ADVAMED from 2013 – 2019 and has also held executive positions at Invatec, PercuSurge, Boston Scientific, SciMed Life Systems, Olympus and Baxter.

About SoundBite

SoundBite Medical Solutions Inc. is developing a proprietary shock wave platform technology to address significant unmet clinical needs in interventional vascular and treatment. Through an elegant combination of hardware and software, it can, in a controlled manner, deliver high amplitude shock wave pulses through guidewires and other interventional tools, to specifically address highly calcified and fibrotic tissue, in the diseased cardio vascular walls, resulting in restoring blood passage while leaving healthy, elastic arterial tissue unharmed.
For information on SoundBite Medical Solutions, please contact Mandy Di Lazzaro, Director, HR & Communications ([email protected]) or Dr. Francis Bellido, CEO ([email protected]), SoundBite Medical Solutions, 2300 Alfred Nobel, Technoparc St-Laurent, Montreal Québec H4S 2A4.
For additional information visit www.soundbitemedical.com

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.

SoundBite Medical Solutions Was Honored with the “Prix Genie innovation 2019” by the Order of Engineers of Quebec

Posted on by
artery

MONTREAL – June 6, 2019 – SoundBite Medical Solutions Inc. (SBMS) today announced that Martin Brouillette, Cofounder & Chief Technology Officer, along with the SoundBite Team, was honored with the “Prix Genie innovation 2019” at the 15th “Soirée de l’Excellence en génie” on Wednesday, May 29, 2019, at Salon 1861 in Montréal.

The goal of the Prix Génie Innovation is to encourage innovative engineering by recognizing its value both in terms of the results achieved and the efforts made. This year the SoundBite Team was awarded this prize in recognition of the SoundBite system development, which represents a major innovative breakthrough in CTO treatment resulting in improved crossing success rate and patients’ quality of life.

“This award is the direct result of the efforts and dedication of our excellent team of employees, and we are honored to contribute to the visibility of Québec’s engineering expertise at home and abroad,” said Martin Brouillette.

About SoundBite Medical Solutions

SoundBite is a privately-held medical device company developing products in the field of vessel preparation for the management and treatment of calcified and occlusive lesions in coronary and peripheral arterial diseases. SoundBite will leverage its shock wave technology platform to clinically and commercially validate its calcium management medical devices with active wires and microcatheters. Peripheral artery disease (PAD) and coronary artery disease (CAD) affect more than 12 million & 16 million people in the US, respectively.

For additional information visit www.soundbitemedical.com

For information on SoundBite Medical Solutions, please contact Mandy Di Lazzaro, Director, Human Resources & Communications ([email protected]) or Francis Bellido, CEO ([email protected]), SoundBite Medical Solutions, 2300 Alfred Nobel, Technoparc St-Laurent, Montreal Québec H4S 2A4

Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.

SoundBite Medical Solutions Announces the Presentation of Their Technology During an Episode of the Show “Découverte” on ICI Radio-Canada Télé

Posted on by
artery

MONTREAL – February 19, 2019 – SoundBite Medical Solutions Inc. (SBMS) today announced that their shockwave technology was presented on Sunday evening by Dr. Stephane Rinfret, MD, SM, FRCPC, Chief of Interventional Cardiology at the McGill University Health Center (MUHC) on a science television show called “Découverte.”

“We are delighted that our technology has attracted so much attention from a show as prestigious as “Découverte.” The program provides an excellent explanation of the therapeutic challenges posed by calcified chronic total occlusions. I think that the public will appreciate this fine example of Quebec creativity and its potential to solve a significant unmet medical need,” said Francis Bellido, President and CEO of SBMS.

Link to watch this episode: https://ici.radio-canada.ca/tele/decouverte/site/segments/reportage/106268/ondes-choc-artere (at 34: 07/42: 42)

About SoundBite Medical Solutions

SoundBite is a privately-held medical device company developing products in the field of vessel preparation for the management and treatment of calcified and occlusive lesions in coronary and peripheral arterial diseases. SoundBite will leverage its shock wave technology platform to clinically and commercially validate its calcium management medical devices with active wires and microcatheters. Peripheral artery disease (PAD) and coronary artery disease (CAD) affect more than 12 million & 16 million people in the US, respectively.

For additional information visit www.soundbitemedical.com

For information on SoundBite Medical Solutions, please contact Mandy Di Lazzaro, Director, Human Resources & Communications ([email protected]) or Francis Bellido, CEO ([email protected]), SoundBite Medical Solutions, 2300 Alfred Nobel, Technoparc St-Laurent, Montreal Québec H4S 2A4

Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.

Newer posts